Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00009984
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00005966
- Locations
- 🇵🇪
Instituto de Enfermedades Neoplasicas, Lima, Peru
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay, Wisconsin, United States
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00006226
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- California Cancer Consortium
- Registration Number
- NCT00022607
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00022581
- Locations
- 🇺🇸
Cancer and Leukemia Group B (CALGB) Research Base, Chicago, Illinois, United States
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 139
- Registration Number
- NCT00041080
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00025506
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Target Recruit Count
- 450
- Registration Number
- NCT00028886
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱Isala Klinieken - locatie Sophia, Zwolle, Netherlands
🇳🇱Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 30
- Registration Number
- NCT00004876
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 147
- Registration Number
- NCT00040937
- Locations
- 🇺🇸
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
🇺🇸Community Medical Center, Missoula, Montana, United States
🇺🇸Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.